Timothy P. Flanigan, MD HIV and Women's Core Co-Director
Mailing Address:	The Miriam Hospital 164 Summit Avenue Providence, RI 02906
Telephone:	(401) 793-7152
Email:	Tflanigan@Lifespan.org

Dr. Timothy P. Flanigan is the Chief of the Division of Infectious Diseases of the Department of Medicine at Brown University. At the Miriam Hospital Immunology Center he provides comprehensive HIV care and participates in clinical care and research at the Rhode Island Prison.

Dr. Flanigan initially focused his research efforts on the parasite Cryptosporidium parvum which is the leading cause of chronic diarrhea worldwide among HIV infected individuals (NIAID 1 K08-AI001085). Upon coming to Brown University in 1991 to join Dr. Charles Carpenter, he helped develop a network of primary care for HIV infected individuals with a particular focus on women, substance abusers and individuals leaving prison. He developed the HIV in Prison Program in the single RI correctional facility. Prisoners are linked to community based resources upon release. Over 70% of Rhode Island HIV infected prisoners link with primary medical care at The Miriam Immunology Center upon release from prison. This program has resulted in a decrease in documented recidivism rates.

Dr. Flanigan has been principal investigator on two prevention grants: CDC Project Start, to develop HIV and STD intervention for young men leaving prison, and the SAMHSA funded Project Shield to develop group HIV and STD intervention among substance abusing adolescents. He is the principal investigator of the Brown University NIH AIDS Clinical Trials Unit and a training grant from the National Institute of Drug Abuse on diagnosis, prevention, and treatment of HIV and other infectious consequences of substance abuse. He is an associate director of the Brown University Fogarty Program to train and mentor overseas investigators in the areas of HIV, AIDS and opportunistic infections. He is also principle investigator of an NIH R01 grant (DA013767-02) designed to study the effectiveness of once daily directly observed antiretroviral therapy (DOT) for the treatment of hard-to-reach populations.